Vifor Pharma Appoints Gregory Oakes as President North America and Member of the Executive Committee
1.9.2020 08:00:00 EEST | Business Wire | Press release
Regulatory News:
Vifor Pharma today announced the appointment of Gregory Oakes as EVP, President North America and member of the Vifor Pharma Executive Committee as of September 1, 2020.
Gregory Oakes has a proven track record of building and leading organizations across multiple therapeutic areas and geographies and has extensive launch and US Market Access experience. He joins from Amgen where he served as Corporate Vice President, Global Integration Lead for Otezla. In this role, he led the integration and commercialization of the $2B brand and successfully positioned it for sustained growth.
Prior to Amgen, Greg was Corporate Vice President and US General Manager at Celgene and previously held several executive positions at Novartis in the US. He began his career at Schering-Plough (Merck) where he worked in executive roles both in the US and Europe.
He received a Master of Business Administration (MBA) from Clemson University and a Bachelor of Science (BS) in Marketing and Business Administration from Edinboro University, both in the US.
Gregory Oakes succeeds Patrick Treanor who joined Relypsa in 2015 to establish the sales organisation for the US launch of Veltassa®. For the past two years as President US, Patrick was instrumental in leading the commercialisation strategy of Veltassa® and aiding Vifor in the integration of Relypsa towards our goal of becoming the leader in nephrology and cardio-renal therapies. Patrick has decided for personal reasons to pursue opportunities outside of Vifor Pharma.
Stefan Schulze, CEO of Vifor Pharma Group comments; “We are delighted that Gregory will join Vifor Pharma as President North America. He has a proven track record of overseeing highly successful acquisitions, growing product portfolios across multiple therapeutic areas and brings a wealth of commercialisation experience. We look forward to working with him to successfully drive and execute our ambitious growth plans in the US.
We would like to take this opportunity to thank Patrick for his dedicated leadership and outstanding contributions to our success over the past 5 years. Patrick played a pivotal role in the success and integration of Relypsa and we wish him the very best for his future endeavours, both professionally and personally.”
Vifor Pharma Group is a global pharmaceuticals company headquartered in Switzerland. It aims to become the global leader in iron deficiency, nephrology and cardio-renal therapies. The company is the partner of choice for pharmaceuticals and innovative patient-focused solutions. Vifor Pharma Group strives to help patients around the world with severe and chronic diseases lead better, healthier lives. The company develops, manufactures and markets pharmaceutical products for precision patient care. Vifor Pharma Group holds a leading position in all its core business activities and consists of the following companies: Vifor Pharma; Vifor Fresenius Medical Care Renal Pharma (a joint company with Fresenius Medical Care); Relypsa; and OM Pharma. Vifor Pharma Group is listed on the Swiss Stock Exchange (SIX Swiss Exchange, VIFN, ISIN: CH0364749348).
For more information, please visit viforpharma.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200831005501/en/
Contact information
Media Relations
Nathalie Ponnier
Global Head Corporate Communications
+41 79 957 96 73
media@viforpharma.com
Investor Relations
Julien Vignot
Head of Investor Relations
+41 58 851 66 90
investors@viforpharma.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Dubai Culture Opens Registration for ISEA2026 Dubai26.10.2026 14:09:00 EET | Press release
Dubai Culture and Arts Authority (Dubai Culture) has opened registration for the 31st International Symposium on Electronic/Emerging Art (ISEA2026 Dubai), taking place from 6 to 15 November 2026 under the theme ‘ELYAH: Constellating Place, Data and Identity’. The symposium will be the largest edition to date, bringing together artists, researchers, and innovators from around the world to explore the intersection of art, science, and technology and exchange perspectives on the future of contemporary creative practice. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261026652826/en/ Dubai Culture Opens Registration for ISEA2026 Dubai (Graphic: AETOSWire) The event supports Dubai Culture’s efforts to advance the digital arts ecosystem, deliver on its Digital Arts Roadmap objectives, and empower local talent. It also reinforces Dubai’s position as a global cultural reference, a leader in innovation, a driver of the creative econo
Agendia Unveils Clinical Validation of AI-Driven Digital Pathology Approach26.10.2026 14:00:00 EET | Press release
Agendia, Inc., a leader in precision oncology for breast cancer, recently presented research introducing its investigational artificial intelligence (AI)-driven digital pathology approach for the MammaPrint®70-gene recurrence signature at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid. The podium presentation, delivered by co-founder and Chief Research Officer, Laura van ’t Veer, Ph.D., detailed the development and clinical validation of a deep learning pipeline that can infer MammaPrint (MP) risk categories directly from hematoxylin and eosin (H&E)-stained, whole-slide images (WSIs). The company also presented two additional posters highlighting data from the prospective, real-world FLEX Study (NCT03053193). “AI has been part of Agendia’s scientific foundation from the beginning and this study represents its continued evolution,” said Dr. Laura van ‘t Veer. "For the first time, we are presenting our work exploring whether the biological information represente
C.H. Robinson Debuts Lean AI for Ocean Shipping, Air Freight and Customs26.10.2026 14:00:00 EET | Press release
As the global leader in Lean AI, C.H. Robinson has launched new AI agents that perform work in ocean shipping, air freight and customs brokerage. They represent an expansion of the company’s Lean AI capabilities into freight forwarding, for the benefit of more customers, and into work so complex that a single shipping task can require over a dozen AI agents working in tandem. Continuing to disrupt itself and the industry, the company’s new tech brings substantial speed-to-market gains, precision and agility to customers’ supply chains without sacrificing human oversight or personal attention. The new tech includes: Price-quoting for ocean and air cargo: AI has determined and delivered over 80,000 price quotes for over 3,600 customers. Quotes that used to take a day for an air shipment and two to three days for an ocean shipment now take two to three minutes. Ocean booking: AI has begun to manage the thousands of booking requests C.H. Robinson receives every week. Customs: AI helps with
TVS Motor Company Returns to EICMA With New Models for Europe26.10.2026 13:45:00 EET | Press release
TVS Motor Company (TVSM), a global leader in two- and three-wheeler manufacturing, returns to EICMA in Milan this November, one year after its debut at the world’s largest two-wheeler exhibition. The company will present new models for Europe at a press conference on Tuesday, 3 November at 10:00 CET. The TVS stand is in Hall 18, Stand I64. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261026990290/en/ TVS Motor Company will present new models for Europe at a press conference on Tuesday, 3 November at 10:00 CET at EICMA this year. EICMA 2025 marked the beginning of TVS Motor's European growth journey. Since then, the company has focused on establishing the foundations for long-term success, building its dealer network, aftersales capabilities and customer support infrastructure across key markets. In Italy, its first European market, TVS now works with around 100 dealers. Retail sales in Italy are up 110% this year to Septem
Two-Year Data of Pimicotinib Demonstrated Durable Tumor Control and Sustained Improvement in TGCT Symptoms and Joint Function26.10.2026 13:00:00 EET | Press release
Merck, a leading science and technology company, today announced new two-year follow-up results from the Phase 3 MANEUVER study evaluating pimicotinib in patients with tenosynovial giant cell tumor (TGCT). The study showed that among patients initially randomized to pimicotinib, improvements in symptoms and joint function were observed as early as Week 5, sustained through two years, and continued to improve over time. Tumor responses remained robust1 and durable,2 and the safety profile was consistent with previous analyses. The findings are being presented today in the Sarcoma poster session at the European Society for Medical Oncology (ESMO) Congress 2026 (Presentation # 3747P). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261022786567/en/ David Weinreich, Global Head of R&D and Chief Medical Officer for the Healthcare business of Merck "For people living with TGCT, the impact of the disease is often felt through persis
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom